Clinical need

There remain several key challenges in preventing and treating acute and chronic infections globally. Conventional approaches and antibiotics have achieved much, but with overuse and inappropriate usage they are are now being challenged by resistance. In addition, and particularly in  chronic infections, clinicians are faced with biofilm production which unfortunately renders common antibiotics useless.

With MHL’s RO® topical surface active technology, we have the ability to tackle these challenges. RO® will be able to prevent infections in most surgical settings, treat post surgical infections whilst also aiding wound healing. It will change the standard of care in chronic infections including wounds, chronic sinusitis and urinary tract infections, which together constitute a major global health burden. RO®’s inherent properties of biofilm penetration, tissue regeneration added to the antimicrobial impact, independent of the organism and its resistance profile, will contribute to a major advance in standard of care and offers the hope of reducing antibiotic usage thus reducing the potential for resistance development.

The technology has the potential to be expanded into other applications to confront systemic infections.   Thus, RO® technology brings the promise of being “much more than a conventional antibiotic” with an elegant manifestation of a naturally occurring mechanism.

Reactive Oxygen® Technology Platform

The first generation of Reactive Oxygen® has been commercialised in the UK as a CE marked medical device called SurgihoneyRO™, this is in gel format and has proven extremely effective in real world settings, particularly against potent antibiotic resistant infections.

For more information about SurgihoneyRO™ and information on how to buy, please follow this link to H&R Healthcare.

Reactive Oxygen® is now being developed in a number of pathways, based on a refined and improved formula which is entirely synthetic and has proven to be more potent and stable than the first generation SurgihoneyRO™.  The lead synthetic formulation, RO® 101, can potentially be taken into wider therapeutic areas and applications as a device or pharmaceutical.

Development pathways being worked on with leading academics include (but are not limited to):

gel (SurgihoneyRO™ in market – RO®101 version being developed)
dry powder
dry powder which converts to gel on contact with wound, sealing wound site and slowly breaking down over time so it does not need to be debrided in the future
nano-spun web to be combined with stem cells, promoting stem cell proliferation and preventing infection
systemic nanoparticle and antigen technology

Matoke is actively exploring a range of development pathways for both medical devices and medicinal products.​

 

Evidence